Online inquiry

IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2699MR)

This product GTTS-WQ2699MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD19&CD3E gene. The antibody can be applied in Diffuse Large B Cell Lymphoma (DLBCL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Mus musculus
RefSeq NM_001178098.2; NM_000733.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930; 916
UniProt ID P15391; P07766
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2699MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9062MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA IMC-A12
GTTS-WQ4482MR IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-931699
GTTS-WQ13136MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-04360365
GTTS-WQ1621MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-910
GTTS-WQ15620MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA VAY-736
GTTS-WQ2043MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AHLX-20
GTTS-WQ2078MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AIN457
GTTS-WQ7375MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FZD8-Fc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW